Virtu Financial’s Creative Medical Technology CELZ Stock Holding History

Virtu Financial’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,374	Closed	-$85K	–	1368
2024 Q1	$85K	Buy	+16,374	New	+$76.2K	0.01%	945
2023 Q2	–	Sell	-5,183	Closed	-$26K	–	1561
2023 Q1	$26K	Buy	5,183 +330	+7%	+$1.87K	﹤0.01%	1195
2022 Q4	$18K	Sell	4,853 -604	-11%	-$2.49K	﹤0.01%	1287
2022 Q3	$24K	Buy	+5,457	New	+$37K	﹤0.01%	1354

Other funds holding CELZ

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Virtu Financial's CELZ Position: Q2 2024 in Review

Virtu Financial sold out of Creative Medical Technology (CELZ) in Q2 2024, closing a stake of 16,374 shares — an estimated $85K sold.

Virtu Financial first reported a position in CELZ in Q3 2022 and held it in 4 quarters. The position peaked at $85K in Q1 2024. 9 funds tracked by Wall St. Rank hold CELZ as of Q2 2024.

Virtu Financial reported no remaining Creative Medical Technology position as of Q2 2024 after selling out during the quarter.
Virtu Financial sold 16,374 Creative Medical Technology shares in Q2 2024, an estimated $85K.
Virtu Financial first reported a position in Creative Medical Technology in Q3 2022 and held it in 4 quarters.
Virtu Financial's Creative Medical Technology position peaked at $85K in Q1 2024.
9 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.